A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

Complement in therapy and disease

(2015) Joost P.M. Melis et al.   MOLECULAR IMMUNOLOGY

Immunoglobulin G1 Fc Domain Motions: Implications for Fc Engineering

(2014) Martin Frank et al.   JOURNAL OF MOLECULAR BIOLOGY

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

A simple, robust and highly efficient transient expression system for producing antibodies

(2013) Tom Vink et al.   METHODS

Revisiting the Role of Glycosylation in the Structure of Human IgG Fc

(2012) M. Jack Borrok et al.   ACS Chemical Biology

Effect of zinc on human IgG1 and its FcγR interactions

(2012) Sophie Sibéril et al.   IMMUNOLOGY LETTERS

Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis

(2012) Thomas A. Bowden et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Evaluation of Electrospray Ionization Mass Spectrometry as a Tool for Characterization of Small Soluble Protein Aggregates

(2011) Guanbo Wang et al.   ANALYTICAL CHEMISTRY

Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans

(2011) Tsunehiro Mizushima et al.   GENES TO CELLS

Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition

(2011) M. B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Quantitative Analysis of the Interaction Strength and Dynamics of Human IgG4 Half Molecules by Native Mass Spectrometry

(2011) Rebecca J. Rose et al.   STRUCTURE

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material

(2010) J. S. CROWE et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

(2010) Gregory L. Moore et al.   mAbs

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

Specific interactions in high concentration antibody solutions resulting in high viscosity

(2009) Sandeep Yadav et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Structural Difference in the Complement Activation Site of Human IgG1 and IgG3

(2009) T. E. Michaelsen et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

(2008) M. Dechant et al.   CANCER RESEARCH

Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells

(2008) J. O. Richards et al.   MOLECULAR CANCER THERAPEUTICS

Native mass spectrometry: a bridge between interactomics and structural biology

(2008) Albert J R Heck   NATURE METHODS